{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:04:54Z","timestamp":1785168294922,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High HBV-DNA load in pregnant women increases the risk of vertical transmission to infants. Tenofovir disoproxil fumarate (TDF) is an effective antiviral treatment, but its safety and efficacy in breastfeeding mothers with high HBV-DNA loads remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study included 210 high HBV-DNA load mothers, divided into a TDF-BF Group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009110) that continued TDF postpartum and breastfed, and a Non-TDF-BF Group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009100) that discontinued TDF postpartum but breastfed. Primary outcomes were HBV transmission, infant HBV serostatus, neonatal safety outcomes, and maternal outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The TDF-BF Group had significantly lower rates of vertical HBV transmission (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05) and HBsAg positivity at 12 months (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05) compared to the Non-TDF-BF Group. A higher proportion of infants in the TDF-BF Group had protective levels of anti-HBs at 12 months (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.046, indicating borderline significance). Infant safety outcomes related to growth were comparable between groups, but the TDF-BF Group had significantly higher serum creatinine levels and lower serum phosphate levels (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05, raising a potential signal for renal function differences). Maternal outcomes favored the TDF-BF Group, with better HBV-DNA suppression and ALT normalization.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Postpartum continuation of TDF and breastfeeding is an effective and safe strategy for reducing vertical HBV transmission and promoting infant immunity in high HBV-DNA load mothers. Notably, Tenofovir was not detected in the infant plasma, supporting the safety of this approach.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1743985","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T07:29:44Z","timestamp":1770622184000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Postpartum TDF continuation in high HBV-DNA mothers: safety for breastfeeding and enhanced infant immunity"],"prefix":"10.3389","volume":"13","author":[{"given":"Dongxiang","family":"Han","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shijiazhuang Maternal and Child Health Hospital","place":["Shijiazhuang, Hebei Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Gen","sequence":"additional","affiliation":[{"name":"Delivery Room, Shijiazhuang Maternal and Child Health Hospital","place":["Shijiazhuang, Hebei Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Physical Examination, Shijiazhuang Maternal and Child Health Hospital","place":["Shijiazhuang, Hebei Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiu","family":"Du","sequence":"additional","affiliation":[{"name":"Laboratory Department, Shijiazhuang Maternal and Child Health Hospital","place":["Shijiazhuang, Hebei Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weisha","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shijiazhuang Maternal and Child Health Hospital","place":["Shijiazhuang, Hebei Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Shijiazhuang Maternal and Child Health Hospital","place":["Shijiazhuang, Hebei Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Delivery Room, Shijiazhuang Maternal and Child Health Hospital","place":["Shijiazhuang, Hebei Province, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.cld.2023.05.007","article-title":"Maternal-to-child transmission of hepatitis B virus and hepatitis delta virus","volume":"27","author":"Aliasi-Sinai","year":"2023","journal-title":"Clin Liver Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.21037\/tp-23-266","article-title":"Decreased placental TLR3 is associated with hepatitis B virus vaccine responsiveness in infants born to HBsAg-positive mothers","volume":"12","author":"Wu","year":"2023","journal-title":"Transl Pediatr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study","volume":"8","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1122048","DOI":"10.3389\/fimmu.2023.1122048","article-title":"Effects of hepatitis B virus infection and strategies for preventing mother-to-child transmission on maternal and fetal T-cell immunity","volume":"14","author":"Lu","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1111\/liv.15249","article-title":"Tenofovir disoproxil fumarate therapy to prevent hepatitis B virus vertical transmission-A review of maternal and infant outcomes","volume":"42","author":"Samadi Kochaksaraei","year":"2022","journal-title":"Liver Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/jvh.13628","article-title":"Kinetics of hepatitis B surface antigen in pregnant women with and without tenofovir disoproxil fumarate","volume":"29","author":"Chang","year":"2022","journal-title":"J Viral Hepat"},{"key":"B7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.18926\/AMO\/66913","article-title":"Evaluation of the efficacy and safety of tenofovir disoproxil fumarate in intercepting mother-to-child transmission of hepatitis B virus","volume":"78","author":"Han","year":"2024","journal-title":"Acta Med Okayama"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e3324","DOI":"10.1093\/cid\/ciaa1939","article-title":"Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study","volume":"73","author":"Zeng","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3855\/jidc.17516","article-title":"HBeag testing is better than quantitative HBsAg assay as an alternative to HBV DNA assay among HBV-infected pregnant women","volume":"17","author":"Nguyen","year":"2023","journal-title":"J Infect Dev Ctries"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1016\/j.vaccine.2023.04.036","article-title":"A phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)","volume":"41","author":"Martinon-Torres","year":"2023","journal-title":"Vaccine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1080\/22221751.2022.2071172","article-title":"Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups","volume":"11","author":"Ning","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/PHH.0000000000001857","article-title":"Mother-to-child transmission of HBV infection by preventive interventions in Southern Vietnam\u2019s hospitals","volume":"30","author":"Hoang","year":"2024","journal-title":"J Public Health Manag Pract"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.2147\/IDR.S359113","article-title":"Intrauterine infection and mother-to-child transmission of hepatitis B virus: route and molecular mechanism","volume":"15","author":"Zhao","year":"2022","journal-title":"Infect Drug Resist"},{"key":"B14","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/MPG.0000000000003765","article-title":"Inadequate hospital practices to prevent mother-to-child transmission of hepatitis B virus infection: a European survey","volume":"76","author":"Pinon","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"967","DOI":"10.14218\/JCTH.2022.00332","article-title":"Strategies to prevent mother-to-child transmission of hepatitis B virus","volume":"11","author":"Sintusek","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2214-109X(22)00026-2","article-title":"Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study","volume":"10","author":"Shimakawa","year":"2022","journal-title":"Lancet Glob Health"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1111\/liv.15873","article-title":"Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: maternal ALT trajectory and infant outcomes","volume":"44","author":"Chen","year":"2024","journal-title":"Liver Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.14309\/ajg.0000000000003122","article-title":"Expected 8-week prenatal vs 12-week perinatal tenofovir alafenamide prophylaxis to prevent mother-to-child transmission of hepatitis B virus: a multicenter, prospective, open-label, randomized controlled trial","volume":"120","author":"Zeng","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.2024.22952","article-title":"Tenofovir and hepatitis B virus transmission during pregnancy: a randomized clinical trial","volume":"333","author":"Pan","year":"2025","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1111\/liv.16028","article-title":"A pilot integrated model nurse clinic increases the uptake of antiviral treatment for the prevention of mother-to-child transmission of HBV","volume":"44","author":"Hui","year":"2024","journal-title":"Liver Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/cid\/ciae288","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for preventing vertical transmission in chronic hepatitis B mothers: a systematic review and meta-analysis","volume":"79","author":"Pan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9362","DOI":"10.21037\/apm-21-1560","article-title":"Comparison of HBV-DNA and HBeAg as antiviral therapeutic indicators among HBV-infected pregnant women: a systematic review and meta-analysis","volume":"10","author":"Liu","year":"2021","journal-title":"Ann Palliat Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/jvh.13459","article-title":"Adherence to pregnancy hepatitis B care guidelines in women and infants in the United States and evaluation of two interventions to improve care: a multicentre hospital-based study","volume":"28","author":"Kushner","year":"2021","journal-title":"J Viral Hepat"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.26355\/eurrev_202303_31580","article-title":"Is the use of Tenofovir Dipivoxil fumarate effective and safe in preventing vertical transmission in pregnant women with chronic HBV with high viral load?","volume":"27","author":"Aladag","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"734760","DOI":"10.3389\/fphar.2021.734760","article-title":"Distribution evaluation of tenofovir in the breast milk of mothers with HBeAg-positive chronic HBV infection after treatment with tenofovir alafenamide and tenofovir disoproxil fumarate by a sensitive UPLC-MS\/MS method","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3904\/kjim.2018.465","article-title":"Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis","volume":"36","author":"Lee","year":"2021","journal-title":"Korean J Intern Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3851\/IMP3345","article-title":"Clinical efficacy and safety in telbivudine- or tenofovir-treated hepatitis B e antigen-positive pregnant women","volume":"25","author":"Deng","year":"2020","journal-title":"Antivir Ther"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1743985\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:55:07Z","timestamp":1771926907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1743985\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":27,"alternative-id":["10.3389\/fped.2025.1743985"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1743985","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"1743985"}}